Vimarsana.com

Latest Breaking News On - Phenomex inc - Page 1 : vimarsana.com

Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Berkeley
California
United-states
Steve-williamson
John-mckune
Brian-johnston
Pulmonx-zephyr
Mehul-joshi
Gilmartin-group
Pulmonx-corporation
Rutgers-university
Rutgers-graduate-school-of-management

Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Berkeley
California
United-states
Steve-williamson
John-mckune
Brian-johnston
Pulmonx-zephyr
Mehul-joshi
Gilead-sciences-inc
Pulmonx-corporation-nasdaq
Gilmartin-group
Pulmonx-corporation

Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Berkeley
California
United-states
Pulmonx-zephyr
Brian-johnston
John-mckune
Mehul-joshi
Steve-williamson
Phenomex-inc
Exchange-commission
Rutgers-graduate-school-of-management
Rutgers-university

Bruker acquires molecular diagnostics provider Elitech for €870M

Continuing its aggressive buying spree, Bruker Corp. entered into a definitive share purchase agreement with Tecfin S.à r.l. to acquire molecular diagnostics (MDx) company Elitechgroup SAS for €870 million (US$943.5 million), excluding the Elitech clinical chemistry business. The deal is expected to close in the second quarter of 2024 and will be funded with a mix of cash on hand and debt financing.

Bruker-corp
Bioworld-medtech
Infectious-diseases
Bruker-corp
Tornado-spectral-systems-inc
Nion-llc
Nanophoton-corp-
Chemspeed-technologies-ag
Phasefocus-holdings-ltd
Phenomex-inc
Zontal-inc

Bruker Reports Fourth Quarter and Full Year 2023 Financial Results

Q4 2023 revenues of $854.5 million, up 20.6% year-over-year ; organic revenue up 15.9% yoy Q4 2023 GAAP EPS of $1.41, including a $0.99 per share gain on PhenomeX acquisition[1]; Q4 2023.

Taiwan
Israel
Ukraine
China
United-states
Russia
Bruker-nano
Frank-laukien
Bruker-biospin
Asia-pacific
Securities-exchange
Bruker-corporation-nasdaq

vimarsana © 2020. All Rights Reserved.